Eribulin mesylate: 1.4mg/m2, ivgtt, 30 minutes, day 1, 8, every 3 weeks

2 trials

Sponsors

Sun Yat-sen University Cancer Center

Conditions

advanced triple-negative breast cancer treated with anthracyclines and taxanes

Phase 2

An exploratory study of the efficacy and safety of the toripalimab in combination with eribulin plus carboplatin regimen in advanced triple-negative breast cancer treated with anthracyclines and taxanes

RecruitingChiCTR2300076899

Sun Yat-sen University Cancer Centeradvanced triple-negative breast cancer treated with anthracyclines and taxanes

Start: 2023-10-24Updated: 2023-10-30

An exploratory study of the efficacy and safety of the sintilimab in combination with eribulin plus carboplatin regimen in advanced triple-negative breast cancer treated with anthracyclines and taxanes

RecruitingChiCTR2400082647

Sun Yat-sen University Cancer Centeradvanced triple-negative breast cancer treated with anthracyclines and taxanes

Start: 2024-04-02Updated: 2024-04-08